![brand logo](/content/dam/AAFP/images/logos_internal/afp-masthead-2024.jpg)
Am Fam Physician. 2023;107(3):online
Author disclosure: No relevant financial relationships.
![](/content/dam/brand/aafp/pubs/afp/MBTN-600x394.gif)
Details for This Review
Study Population: Adults 18 years or older with acute or chronic low back pain in one of three diagnostic groups: radicular low back pain, nonradicular low back pain, or spinal stenosis
Efficacy End Points: Improvement in pain and function, need for surgery, and quality of life
Harm End Points: Adverse events, serious adverse events, transient hyperglycemia, and withdrawal from the trial
![](/content/dam/brand/aafp/pubs/afp/issues/2023/0300/p230A-ut2.gif)
Benefits | Harms |
---|---|
1 in 6 with radicular low back pain was helped: short-term function (two weeks to less than three months of follow-up) | No reported adverse events or serious adverse events, including transient hyperglycemia |
1 in 6 with radicular low back pain was helped: long-term function (12 months or greater follow-up) | |
No other benefits in pain, function, need for surgery, or improvement in quality of life were reported for nonradicular low back pain or spinal stenosis |
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available